FivepHusion

Executive Summary

FivepHusion is an Australian oncology-focused biotechnology company advancing two novel platforms to improve outcomes for patients with solid tumors. Its lead product, Deflexifol™, is an all-in-one formulation of 5-fluorouracil (5-FU) and leucovorin delivered at physiological pH, designed to enhance the efficacy and tolerability of standard chemotherapy. The company is initially targeting colorectal, pancreatic, gastric, and breast cancers, with potential expansion into pediatric brain tumors such as ependymoma. Additionally, FivepHusion licenses the ResectAssist™ platform, which enables localized drug delivery directly into solid tumors, addressing the challenge of achieving therapeutic concentrations at the tumor site while minimizing systemic toxicity. With both programs in Phase 2 development, FivepHusion is well-positioned to address significant unmet needs in oncology, though it remains an early-stage private company with no approved products or disclosed financing history. The combination of innovative reformulation and localized delivery offers a differentiated approach that could generate interest from strategic partners or investors as clinical data mature.

Upcoming Catalysts (preview)

• Q2 2027Phase 2 interim data readout for Deflexifol in colorectal or pancreatic cancer50% success
• Q3 2026ResectAssist clinical trial initiation or partnership announcement60% success
• Q1 2027Regulatory guidance from TGA or FDA on Deflexifol development pathway40% success